|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Managing malignant biliary obstruction in pancreas cancer: Choosing the appropriate strategy显示文摘Most patients with pancreatic cancer develop malignant biliary obstruction.Treatment of obstruction is generally indicated to relieve symptoms and improve morbidity and mortality.First-line therapy consists of endoscopic biliary stent placement.Recent data comparing plastic stents to self-expanding metallic stents(SEMS)has shown improved patency with SEMS.The decision of whether to treat obstruction and the means for doing so depends on the clinical scenario.For patients with resectable disease,preoperative biliary decompression is only indicated when surgery will be delayed or complications of jaundice exist.For patients with locally advanced disease,self-expanding metal stents are superior to plastic stents for long-term patency.For patients with advanced disease,the choice of metallic or plastic stent depends on life expectancy.When endoscopic stent placement fails,percutaneous or surgical treatments are appropriate.Endoscopic therapy or surgical approach can be used to treat concomitant duodenal and biliary obstruction. | Brian R Boulay Mayur Parepally | 2014 | World Journal of Gastroenterology2014，20，28： | 18 |
| 2 | Brain up take of nonsteroidal antiinflammatory drugs: ibuprofen, flurbiprofen, and indomethacin 显示文摘 | Parepally J M Mandula H Smith QR | 2006 | Pharm Res2006，23，6： | 1 |
| 3 | Brain uptake of nonsteroidal anti-inflammatory drugs:ibuprofen,flurbiprofen,and indomethacin显示文摘 | Parepally JM Mandula H Smith QR | 2006 | Pharm Res2006，23，5： | 1 |
| 4 | Brain uptake of nonsteroidal anti-inflammatory drugs:ibuprofen,flurbiprofen,and indomethacin显示文摘 | Parepally JM Mandula H Smith QR | | 0，，05： | 1 |
| 5 | Brain uptake of nonsteroidal antiinflammatory drugs:ibuprofen,flurbiprofen,and indomethacin显示文摘 | Parepally JM Mandula H Smith QR | 2006 | Pharm Res2006，23，6： | 1 |
| 6 | Brain uptake of nonsteroidal anti-inflammatory drugs:ibuprofen,flurbiprofen,and indomethacin显示文摘 | Parepally JM Mandula H Smith QR | | 0，，06： | 1 |
| 7 | Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin显示文摘 | Jagan Mohan R. Parepally Haritha Mandula Quentin R. Smith | 2006 | Pharmaceutical Research2006，，5： | 1 |
| 8 | Brain uptake of nonsteroidal anti-inflammatory drugs:ibuprofen,flurbiprofen,and indomethacin显示文摘 | Parepally JM Mandula H Smith QR | | 0，，05： | 1 |
| 9 | Brain uptake of non- steroidal anti-inflammatory drugs: boprofen, flurbiprofen, and indomethaein显示文摘 | Parepally J M Mandula H Smith Q R | 2006 | Pharm Res2006，23，5： | 1 |
| 10 | Brain uptake of nonsteroidal anti-inflammatory drugs : ibuprofen, flurbiprofen, and indomethacin 显示文摘 | Parepally JM Mandula H Smith QR | 2006 | Pharm Res2006，23，5： | 1 |
| 11 | Silencing profilin-1 inhibits endothelial cell proliferation,migration and cord morphogenesis显示文摘 | Ding ZJ Lambrechts A Parepally M | 2006 | J Cell Sci2006，119，19： | 1 |
| 12 | 显示文摘 | Ding Z Lambrechts A Parepally M | 2006 | J Cell Sci2006，119，19： | 1 |
| 13 | Brain uptake of nonste-roidal antiinflammatory drugs : ibuprofen, flurbiprofen, and indomethacin 显示文摘 | Parepally JM Mandula H Smith QR | 2006 | Pharm Res2006，23，5： | 1 |
| 14 | Brain uptake of nonsteroidal anti- inflammatory drugs : ibuprofen, flurbipro- fen ,and indomethacin显示文摘 | PAREPALLY J M MANDULA H SMITH Q R | 2006 | Pharm Res2006，23，： | 1 |
| 15 | Brain uptake of nonste - roidal antiinflammatory drugs: ibuprofen, flurbiprofen, and indomethacin显示文摘 | Parepally J M Mandula H Smith Q R | 2006 | Pharm Res2006，23，： | 1 |
| 16 | Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites显示文摘AIM To compare features of hepatocellular carcinoma(HCC) in Hispanics to those of African Americans and Whites.METHODS Patients treated for HCC at an urban tertiary medical center from 2005 to 2011 were identified from a tumor registry. Data were collected retrospectively, including demographics, comorbidities, liver disease characteristics, tumor parameters, treatment, and survival(OS) outcomes. OS analyses were performed using Kaplan-Meier method.RESULTS One hundred and ninety-five patients with HCC were identified: 80.5% were male, and 22% were age 65 or older. Mean age at HCC diagnosis was 59.7 ± 9.8 years. Sixty-one point five percent of patients had Medicare or Medicaid; 4.1% were uninsured. Compared to African American(31.2%) and White(46.2%) patients, Hispanic patients(22.6%) were more likely to have diabetes(P = 0.0019), hyperlipidemia(P = 0.0001), nonalcoholic steatohepatitis(NASH)(P = 0.0021), end stage renal disease(P = 0.0057), and less likely to have hepatitis C virus(P < 0.0001) or a smoking history(P < 0.0001). Compared to African Americans, Hispanics were more likely to meet criteria for metabolic syndrome(P = 0.0491), had higher median MELD scores(P = 0.0159), ascites(P = 0.008), and encephalopathy(P = 0.0087). Hispanic patients with HCC had shorter OS than the other racial groups(P = 0.020), despite similarities in HCC parameters and treatment. CONCLUSION In conclusion, Hispanic patients with HCC have higher incidence of modifiable metabolic risk factors including NASH, and shorter OS than African American and White patients. | Neeta K Venepalli Mary V Modayil Stephanie A Berg Tad D Nair Mayur Parepally Priyanka Rajaram Ron C Gaba James T Bui Yue Huang Scott J Cotler | 2017 | World Journal of Hepatology2017，9，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员